Previous 10 | Next 10 |
Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX) +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. ...
Commercial-stage biotech, Intercept Pharmaceuticals (NASDAQ:ICPT) announced an agreement with Europe-based Advanz Pharma (OTCPK:CXRXF) on Thursday to sell some of its foreign units and rights regarding overseas operations. The sale includes a license to commercialize the company’s prim...
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept Additionally, Intercept will receive royalties on any future ex-U...
MORRISTOWN, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 fina...
Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anticipated to report data for the Phase 3 (MAESTRO-NASH) trial. Despite strong funda...
Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded at a new 52-week high today of $185.00. So far today approximately 89.2 million shares have been exchanged, as compared to an average 30-day volume of 923,000 shares. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is currently p...
Abeona Therapeutics (NASDAQ:ABEO) is trading ~6% higher in the pre-market Thursday after the clinical-stage biopharmaceutical company announced the appointment of Joseph Vazzano as its new Chief Financial Officer effective March 31. The appointment made on March 03 follows the resig...
Intercept expects pre-submission meeting with FDA in the 1st half of 2022 as long as new REGENERATE NASH data warrants potential accelerated FDA approval. It is estimated that the global NASH market could reach $20 billion by 2027. Topline results from the phase 3 REVERSE study us...
Intercept Pharmaceuticals, Inc. (ICPT) Q4 2021 Earnings Conference Call March 02, 2022 08:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President & Chief Executive Officer Linda Richardson - Chief Commercial Officer Michelle Berrey - ...
Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...